Association of response to doxycycline and Azithromycin antibiotics therapy with Angiotensin converting enzyme polymorphism in patients with moderate acne vulgaris

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230305057628N1

Enrollment

Registered

2023-03-14

Start date

2023-03-11

Completion date

Unknown

Last updated

2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris. Acne vulgaris

Interventions

Intervention 1: Intervention group: At first, the patients are examined by a dermatologist and the severity of their acne is measured based on the Michelson acne score, and the patients are subjected

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: Acne vulgaris with moderate severity according to the MAS SCORE classification system Suffering from acne vulgaris with moderate severity according to Weishampain's classification system

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Angiotensin converting enzyme gene polymorphism. Timepoint: After the end of the treatment period. Method of measurement: PCR and electrophoresis.;Response to treatment. Timepoint: Before starting the treatment, after the end of the treatment. Method of measurement: MAS score.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contacthamide mohammadzadeh

Gonabad University of Medical Sciences

Mohammadzadeh.hamideh@yahoo.com+98 51 5723 6832

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026